|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: P2RY2 |
Gene summary for P2RY2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | P2RY2 | Gene ID | 5029 |
| Gene name | purinergic receptor P2Y2 | |
| Gene Alias | HP2U | |
| Cytomap | 11q13.4 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | P41231 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5029 | P2RY2 | P5T-E | Human | Esophagus | ESCC | 2.31e-05 | 1.15e-01 | 0.1327 |
| 5029 | P2RY2 | P12T-E | Human | Esophagus | ESCC | 1.43e-04 | 6.08e-02 | 0.1122 |
| 5029 | P2RY2 | P17T-E | Human | Esophagus | ESCC | 2.02e-02 | 1.46e-01 | 0.1278 |
| 5029 | P2RY2 | P20T-E | Human | Esophagus | ESCC | 3.10e-08 | 2.45e-01 | 0.1124 |
| 5029 | P2RY2 | P21T-E | Human | Esophagus | ESCC | 7.76e-12 | 2.31e-01 | 0.1617 |
| 5029 | P2RY2 | P23T-E | Human | Esophagus | ESCC | 3.89e-06 | 2.72e-01 | 0.108 |
| 5029 | P2RY2 | P26T-E | Human | Esophagus | ESCC | 7.58e-08 | 8.10e-02 | 0.1276 |
| 5029 | P2RY2 | P27T-E | Human | Esophagus | ESCC | 2.69e-03 | 5.16e-02 | 0.1055 |
| 5029 | P2RY2 | P28T-E | Human | Esophagus | ESCC | 3.22e-05 | 1.44e-01 | 0.1149 |
| 5029 | P2RY2 | P31T-E | Human | Esophagus | ESCC | 6.44e-04 | 5.35e-02 | 0.1251 |
| 5029 | P2RY2 | P36T-E | Human | Esophagus | ESCC | 2.29e-02 | 1.27e-01 | 0.1187 |
| 5029 | P2RY2 | P37T-E | Human | Esophagus | ESCC | 4.61e-02 | 5.97e-02 | 0.1371 |
| 5029 | P2RY2 | P44T-E | Human | Esophagus | ESCC | 5.81e-09 | 3.24e-01 | 0.1096 |
| 5029 | P2RY2 | P49T-E | Human | Esophagus | ESCC | 1.57e-05 | 3.94e-01 | 0.1768 |
| 5029 | P2RY2 | P62T-E | Human | Esophagus | ESCC | 8.92e-04 | 1.44e-01 | 0.1302 |
| 5029 | P2RY2 | P75T-E | Human | Esophagus | ESCC | 5.60e-04 | 1.18e-01 | 0.1125 |
| 5029 | P2RY2 | P80T-E | Human | Esophagus | ESCC | 1.36e-07 | 2.39e-01 | 0.155 |
| 5029 | P2RY2 | P83T-E | Human | Esophagus | ESCC | 2.39e-24 | 6.97e-01 | 0.1738 |
| 5029 | P2RY2 | P89T-E | Human | Esophagus | ESCC | 7.89e-09 | 5.12e-01 | 0.1752 |
| 5029 | P2RY2 | P107T-E | Human | Esophagus | ESCC | 1.83e-11 | 2.67e-01 | 0.171 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005087819 | Oral cavity | OSCC | regulation of body fluid levels | 179/7305 | 379/18723 | 6.19e-04 | 3.50e-03 | 179 |
| GO:00702543 | Oral cavity | OSCC | mucus secretion | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| P2RY2 | SNV | Missense_Mutation | novel | c.953N>T | p.Arg318Leu | p.R318L | P41231 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-AO-A0J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| P2RY2 | SNV | Missense_Mutation | c.1004N>A | p.Arg335Lys | p.R335K | P41231 | protein_coding | tolerated(0.49) | benign(0) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| P2RY2 | SNV | Missense_Mutation | novel | c.667C>T | p.Arg223Trp | p.R223W | P41231 | protein_coding | deleterious(0.02) | probably_damaging(0.946) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| P2RY2 | SNV | Missense_Mutation | novel | c.821N>A | p.Leu274Gln | p.L274Q | P41231 | protein_coding | deleterious(0.02) | probably_damaging(0.986) | TCGA-A6-3808-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| P2RY2 | SNV | Missense_Mutation | c.763N>A | p.Ala255Thr | p.A255T | P41231 | protein_coding | tolerated(0.16) | benign(0.066) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| P2RY2 | SNV | Missense_Mutation | novel | c.674N>C | p.Leu225Pro | p.L225P | P41231 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| P2RY2 | SNV | Missense_Mutation | rs148967472 | c.530N>A | p.Arg177His | p.R177H | P41231 | protein_coding | deleterious(0.03) | possibly_damaging(0.833) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| P2RY2 | SNV | Missense_Mutation | c.529N>T | p.Arg177Cys | p.R177C | P41231 | protein_coding | deleterious(0.01) | probably_damaging(0.932) | TCGA-AY-A8YK-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | CR | |
| P2RY2 | SNV | Missense_Mutation | c.428N>A | p.Arg143His | p.R143H | P41231 | protein_coding | tolerated(0.25) | benign(0.035) | TCGA-D5-5539-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fu | PD | |
| P2RY2 | SNV | Missense_Mutation | c.248C>T | p.Ala83Val | p.A83V | P41231 | protein_coding | tolerated(1) | benign(0.012) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5029 | P2RY2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, ION CHANNEL | ATRA | TRETINOIN | 18404486 | |
| 5029 | P2RY2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, ION CHANNEL | Diquafosol | DIQUAFOSOL | ||
| 5029 | P2RY2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, ION CHANNEL | INS37217 | |||
| 5029 | P2RY2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, ION CHANNEL | agonist | 135651410 | CHEMBL1767409 | |
| 5029 | P2RY2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, ION CHANNEL | antagonist | 135649951 | ||
| 5029 | P2RY2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, ION CHANNEL | agonist | 135651592 | ||
| 5029 | P2RY2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, ION CHANNEL | agonist | 135651591 | DIQUAFOSOL | |
| 5029 | P2RY2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, ION CHANNEL | agonist | 178100411 | ||
| 5029 | P2RY2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, ION CHANNEL | antagonist | 329968408 | ||
| 5029 | P2RY2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, ION CHANNEL | agonist | 135650664 |
| Page: 1 2 3 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |